Key terms
About GTBP
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in Brisbane, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GTBP news
Feb 02
7:50pm ET
GT Biopharma trading halted, news pending
Feb 01
11:04am ET
GT Biopharma announces 1-for-30 reverse stock split
Dec 13
6:29am ET
Buy Rating for GT Biopharma: High Efficacy and Expanded Potential in Oncology Therapeutics
Dec 06
9:31am ET
GT Biopharma: ISS, Glass Lewis recommend shareholders vote for proposed items
Dec 04
9:32am ET
GT Biopharma announces IND submission for GTB-3650
GTBP Financials
Key terms
Ad Feedback
GTBP Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GTBP Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
